1. Introduction {#sec0005}
===============

Constant and optimal nutrient and oxygen supply as well as effective removal of metabolic waste products (*e.g.* CO~2~) are ensured by several mechanisms controlling cerebral blood flow. Control of global cerebral circulation is provided by metabolic factors, cerebral autoregulation, and autonomic mechanisms ([@bib0470]). Fine-tuning and continuous adjustment of local cerebral blood flow in accord with the levels of neuronal activity and metabolism are achieved by operation of the neurovascular coupling mechanism. The functional significance of this mechanism arises from 1) the inability of the brain to store significant energy reserves; 2) highly dynamic and regionally heterogeneous metabolism; 3) volume constraints imposed by the cranium; and 4) the need to maximise the efficacy of energy use.

The mechanisms underlying neurovascular coupling have been the subject of intense research interest for the past ∼25 years for two important reasons. Firstly, changes in local brain blood flow which follow changes in neuronal activity provide the physiological basis of blood oxygen level dependent (BOLD) functional MRI (fMRI) imaging ([@bib0085]). Regional cerebral blood flow changes in humans can, therefore, be measured non-invasively and used as a surrogate to assess changes in the neuronal activity ([@bib0035]). Secondly, impaired mechanisms controlling brain blood flow may contribute to cognitive impairment and potentially precipitate the development of dementia/ neurodegenerative disease ([@bib0195]). However, despite continued experimental scrutiny by many research groups, the cellular and molecular mechanisms of the neurovascular response are not fully understood and/or remain controversial. Here, using meta-analysis, we evaluated the results of experimental studies that aimed to identify the signalling mechanism(s) of the neurovascular coupling response. We analysed the relative efficacy of experimental treatments targeting all the hypothesised pathways. Our analysis suggests that a substantial proportion of the neurovascular response is mediated by an as yet unknown mechanism.

2. Metabolic feedback mechanisms {#sec0010}
================================

The physiological significance of the neurovascular response is predicated on the fact that neuronal activity requires copious amounts of energy substrates. Oxygen and glucose are used to generate ATP, which is required to maintain ion gradients and provide energy to fuel the mechanisms of neurotransmitter release/recycling that make neuronal communication and brain information processing possible ([@bib0040]; [@bib0185]). As levels of neuronal activity are believed to be highly heterogeneous across the brain (which has no significant stores of metabolic substrates), blood flow is redirected to support regions of heightened activity.

Feedback mechanisms are fundamental for the operation of all physiological systems, including those which maintain energy homeostasis. A metabolic feedback hypothesis of brain blood flow regulation was proposed by [@bib0385] who observed that products of cerebral metabolism released during brain asphyxia (hypoxia/hypercapnia) dilate cerebral vasculature. These observations led to the hypothesis that signals increasing local brain blood flow are generated in response to a reduction in supply of metabolic substrates and/or accumulation of metabolic waste products ([@bib0225]).

A reduction in the local concentration of oxygen and/or glucose might, therefore, serve as a suitable negative feedback trigger to initiate the neurovascular response. Brain metabolism is argued to be significantly more sensitive to the decreases of oxygen delivery over that of glucose ([@bib0255]). Indeed, experimental studies in anesthetised rats involving raising the arterial concentration of glucose up to ∼18 mmol L^−1^ demonstrated no effect of excess glucose on the neurovascular response ([@bib0475]).

Earlier studies suggested that neurovascular response might be triggered by brain tissue hypoxia associated with the increased neuronal activity ([@bib0300]; [@bib0345]; [@bib0430]). A study conducted in rat brain slices demonstrated that parenchymal oxygen tension determines the polarity of cerebrovascular responses that follow activation of perivascular astrocytes by intracellular Ca^2+^ uncaging ([@bib0155]). More recently astrocytes themselves have been shown to be acutely sensitive to hypoxia ([@bib0020]). Red blood cells have also been proposed to function as oxygen sensors responding with conformational changes to decreases in brain *P*O~2~ during neuronal activation ([@bib0455]). [@bib0135] reported faithful coupling between neuronal activity and local tissue *P*O~2~ decreases upon visual stimulation in the anesthetised cat. However, the magnitude of the neuronal activity-induced transient brain parenchymal *P*O~2~ decreases is small (∼1-5 mmHg) ([@bib0135]; [@bib0355]; [@bib0455]) and neurovascular responses are not affected in conditions of normobaric ([@bib0475]) or hyperbaric hyperoxia in rats ([@bib0265]). In conditions of hyperbaric hyperoxia, enhanced neuronal oxygen consumption would be exceeded by the amount of physically dissolved oxygen. That the neurovascular response is unaffected under hyperbaric hyperoxia would suggest it is unlikely to be triggered by (small) associated decreases in local tissue oxygenation.

Could a build up of metabolic waste products be mediating the neurovascular response? CO~2~, protons and lactate have powerful effects on cerebral vasculature and are generated proportionately with increased brain tissue metabolism.

Astrocytes have been shown to detect local increases in CO~2~ or proton concentrations responding to these stimuli with increases in intracellular \[Ca^2+^\] ([@bib0165]; [@bib0190]), which may lead to the release of vasoactive signalling molecules. Release of lactate *via* several parallel mechanisms, involving certain membrane channels ([@bib0220]; [@bib0400]) is coupled to metabolic signalling pathways ([@bib0120]) and follows enhanced neuronal activity. Yet, the roles of locally produced CO~2~, H^+^ and lactate as potential triggers of the neurovascular response have not been experimentally addressed. There is evidence that brain parenchymal pH does not change or even becomes alkaline due to neuronal activity-induced increases in flow leading to rapid CO~2~ washout and activation of the membrane Ca^2+^-ATPase rapidly removing the excess of extracellular protons ([@bib0095]; [@bib0295]; [@bib0440]).

Taken together, these lines of evidence argue against the importance of metabolic feedback mechanisms in triggering changes in regional cerebral blood flow which follow changes in the neuronal activity. These mechanisms will not be considered further because of the insufficient number of relevant studies meeting our inclusion criteria for meta-analysis (described in detail below).

3. Activity-dependent feed-forward mechanisms {#sec0015}
=============================================

An alternative hypothesis to a feed-forward mechanism centres on the idea that neuronal activity-induced changes in the brain neurochemical milieu mediate neurovascular coupling ([@bib0030]). According to this hypothesis, neurotransmitter(s) released during synaptic activity and/or extracellular K^+^ accumulating as a result of neuronal activity initiate and maintain the neurovascular response ([@bib0280]). Downstream mechanisms have been proposed to involve recruitment of intermediate cell types, including interneurons and astrocytes, which signal to vascular smooth muscle cells and pericytes ([@bib0315]). Significant experimental evidence suggests that signalling within the neurovascular unit could be mediated by several sequential, parallel, competing and/or redundant pathways involving nitric oxide (NO), prostanoids, purines, amongst others ([@bib0030]; [@bib0195]). Hypothesized signalling pathways responsible for the increases in local brain blood flow in response to enhanced neuronal activity are summarized in [Fig. 1](#fig0005){ref-type="fig"}.Fig. 1**Hypothesized signalling mechanisms of the neurovascular coupling.** Schematic illustration of all hypothesized pathways mediating the neurovascular response suggested by the results of studies summarized in Figures 2 and 3. All pathways are depicted assuming equal weighting. 20-HETE, 20-Hydroxyeicosatetraenoic acid; A~2A~, adenosine receptor 2A; AA, arachidonic acid; ACh, acetylcholine; ADO, adenosine; ADP, adenosine diphosphate; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ATP, adenosine triphosphate; cGMP, cyclic guanosine monophosphate; COX, cyclooxygenase; CYP, cytochrome P450; DAGL, diacylglycerol lipase; EET, epoxyeicosatrienoic acid; ENT, ectonucleotidase; EP4, prostaglandin E~2~ receptor 4; EPOX, cytochrome P450 epoxygenase; GABA~A~, γ-aminobutyric acid (GABA) A receptor; GABA~B~, γ-aminobutyric acid B receptor; K~xx~, potassium channels; mAchR, muscarinic acetylcholine (ACh) receptor; mGluR5, metabotropic glutamate receptor 5; NMDAR, *N*-methyl-[d]{.smallcaps}-aspartate receptor; NO, nitric oxide; NOS, nitric oxide synthase; P2X~1~, P2X purinoceptor 1; P2Y~1~, P2Y purinoceptor 1; PG, prostaglandin; PLA2, phospholipase A2; PLD2, phospholipase D2.Fig. 1

As newcomers to this field we found no up-to-date systematic review of experimental data attempting to analyse the relative significance of the proposed signalling pathways. Addressing this need, we conducted a meta-analysis of publications reporting the results of the experimental studies targeting all hypothesized pathways of neurovascular coupling either pharmacologically or genetically.

Initial searches returned hundreds of relevant studies published since the feedforward hypothesis was proposed. In an attempt to distil critical information, meta-analysis was performed using the selection criteria outlined next. Our primary outcome measure was the percent reduction of the cerebrovascular response induced by increased neuronal activity assessed using *in vivo* animal models. The necessary criteria for inclusion were enhanced neuronal activity, recruited by either electrical (*e.g.* forepaw or direct input pathway) or natural (*e.g.* whisker deflection, visual or motor task) stimulation, evoked the neurovascular response measured by recording changes in cerebral vessel diameter, cerebral blood flow, BOLD fMRI or local brain tissue *P*O~2~ in experimental animals. While it is accepted that not all of these measures are exclusively dependent on changes in blood flow only, all have been used as measures of the neurovascular response. Our secondary measure was percent reduction of the cerebral vessel response studied in brain slice preparations *in vitro*. Studies of neurovascular responses evoked by application of receptor agonists (*e.g.* ([@bib0080])), high K^+^ (*e.g.* ([@bib0130])), direct stimulation of the brain area from which the response was measured or involving pathological models (*e.g.* cortical spreading depression ([@bib0350])) were not included in the analysis. A minimum of two experimental studies *in vivo* targeting the same signalling pathway under the above criteria were required for inclusion. Experimental conditions were grouped into categories targeting hypothesised signalling pathways mediated by NO, prostanoids, ATP, adenosine, K^+^ and those aimed at blocking several targets. Means were taken from the control and experimental group data and the effect of a pharmacological agent or genetic manipulation was expressed as a percentage of the control response. The individual data points were then pooled per targeted signalling pathway and plotted with their respective 95% confidence intervals ([Fig. 2](#fig0010){ref-type="fig"}, [Fig. 3](#fig0015){ref-type="fig"}). This analysis standardizes the relative effectiveness of blocking each target or a combination of targets, allowing direct comparisons. Individual data points are tabulated with the original source referenced in Supplementary Table 1 for the primary (*in vivo*) outcome measure.Fig. 2**The effects of blocking hypothesized signalling mechanisms of neurovascular coupling *in vivo.*** Summary plot illustrating the percentage means (with 95% confidence intervals) of neurovascular coupling (NVC) responses that remain in conditions of pharmacological or genetic blockade of hypothesized signalling pathways *in vivo*. Individual data points illustrate the magnitude of the effects of the 79 experimental treatments reported in the publications referenced. \*Multiple category includes the results of experimental studies that combined neuronal NOS (nNOS) inhibition with blockade of at least one other target. References: nNOS; ([@bib0060]; [@bib0070]; [@bib0100]; [@bib0200]; [@bib0230]; [@bib0270]; [@bib0345]; [@bib0410]; [@bib0480]; [@bib0485]; [@bib0490]), Multiple; ([@bib0115]; [@bib0145]; [@bib0260]; [@bib0370]; [@bib0375]; [@bib0425]), ATP; ([@bib0315]; [@bib0435]; [@bib0460]), NOS; ([@bib0005]; [@bib0010]; [@bib0110]; [@bib0145]; [@bib0200]; [@bib0205]; [@bib0210]; [@bib0230]; [@bib0325]; [@bib0370]; [@bib0380]; [@bib0435]; [@bib0485]; [@bib0500]), Epoxygenase; ([@bib0250]; [@bib0365], [@bib0370]), Ach; ([@bib0025]; [@bib0055]; [@bib0240]; [@bib0500]), Adenosine; ([@bib0115]; [@bib0235]; [@bib0310]), COX-2; ([@bib0050]; [@bib0250]; [@bib0330]), AMPA/NMDA; ([@bib0090]; [@bib0250]; [@bib0375]; [@bib0480]), COX; ([@bib0050]; [@bib0065]; [@bib0145]; [@bib0405]), K^+^ Channels; ([@bib0180]; [@bib0280], [@bib0285]), mGluR; ([@bib0090]; [@bib0250]; [@bib0375]; [@bib0395]; [@bib0505]), GABA; ([@bib0240]; [@bib0250]), COX-1; ([@bib0335]; [@bib0375]).Fig. 2Fig. 3**The effects of blocking hypothesized signalling mechanisms of neurovascular coupling *in vitro*.** Summary plot illustrating the percentage means (with 95% confidence intervals) of neurovascular coupling (NVC) responses that remain in conditions of pharmacological or genetic blockade of hypothesized signalling pathways *in vitro*. Individual data points illustrate the magnitude of the effects of the 36 experimental treatments reported in the publications referenced: K^+^ Channels; ([@bib0130]; [@bib0275], [@bib0280]; [@bib0285]; [@bib0495]), COX; ([@bib0130]; [@bib0155]; [@bib0315]), NOS; ([@bib0305]; [@bib0315]; [@bib0505]), ATP; ([@bib0315]), AMPA/NMDA; ([@bib0170]; [@bib0305]; [@bib0315]; [@bib0505]), Epoxygenase; ([@bib0170]; [@bib0315]).Fig. 3

A systematic review constrained by these criteria returned 61 reports, from which we analysed the results of 79 experimental conditions *in vivo* and 36 experimental conditions *in vitro*. Upon aggregation, blockade of neuronal NOS (nNOS) was found to have the largest effect of blocking any individual target, reducing the magnitude of the neurovascular response by 64% (average of the results of 11 *in vivo* studies) ([Fig. 2](#fig0010){ref-type="fig"}). Attempts to inhibit multiple targets simultaneously, all of which included nNOS blockade, resulted in a similar reduction of the response magnitude (by 61%; average of the results of 6 studies) ([Fig. 2](#fig0010){ref-type="fig"}). A potent vasodilator, NO is produced by three NOS isoforms: endothelial NOS (eNOS), nNOS and inducible NOS ([@bib0015]). The temporal profile of inducible NOS activation and deactivation is incompatible with fast control of cerebral blood flow in accordance with neuronal activity. Both eNOS and nNOS are expressed by various cellular components of the neurovascular unit. There is evidence that neurovascular response to somatosensory stimulation is reduced in eNOS deficient mice ([@bib0435]). However, other studies reported that blockade of all NOS isoforms with *N*^ω^-nitro-[l]{.smallcaps}-arginine (L-NNA) attenuated neurovascular response in both the wild type and eNOS-deficient mice ([@bib0045]) but had no effect in conditions of nNOS deficiency ([@bib0290]). Furthermore, the use of non-selective NOS inhibitors was found to have a similar effect on the magnitude of the neurovascular response (reduction by 58%, 14 *in vivo* studies; [Fig. 2](#fig0010){ref-type="fig"}) to that of a pharmacological or genetic nNOS blockade. It is important to note that NOS blockade is associated with a significant reduction of resting cerebral blood flow (by 28% on average; data retrieved from 6 studies that reported baseline changes). Reduction in basal flow *per se* would be expected to increase the relative magnitude of the evoked neurovascular response (as observed, for example, after caffeine administration ([@bib0320])). Depending on the experimental design and particularities of data analysis this may potentially result in overestimation of the neurovascular response in these conditions. However, [@bib0200] applied hypocapnia to induce a comparable reduction in cerebral blood flow as observed following systemic NOS blockade and found no effect of this experimental manoeuvre on the magnitude of the neurovascular response in anesthetised rats.

Thus, NO production by nNOS appears to be critically important for the development of the neurovascular response. Yet, a significant proportion (∼1/3) of the response remains after pharmacological blockade of nNOS. This assumes complete blockade, which is likely as genetic nNOS deletion was found to have an effect of similar magnitude as pharmacological intervention ([@bib0490]). Almost complete enzyme inhibition is possible with pharmacology: for example, Nitro-[l]{.smallcaps}-arginine was reported to inhibit 95 ± 4% of NOS activity when superfused on the cortical surface of anesthetised rats. However, this treatment was associated with a mere 37 ± 4% inhibition of the neurovascular response in the area ([@bib0500]). Another study in anesthetised rats did find a positive correlation between the efficacy of NOS inhibition and the degree reduction of the neurovascular response magnitude in the barrel cortex with  *r^2^* = 0.63 ([@bib0210]). It is important to note that the relative proportion of nNOS expressing neurones varies between different brain areas. In the cerebellar cortex, where the granular layer has the highest level of nNOS expression of all brain areas, blockade of the enzyme was found to completely abolish activity-dependent dilations in slices ([@bib0305]). In the rodent cerebral cortex, the proportion of nNOS expressing neurones is relatively low (0.5--2%), and all these cells are GABAergic interneurons unevenly distributed between different cortical layers ([@bib0445]). One study conducted in anaesthetized rats, reported that addition of a NO donor can restore the full magnitude of the neurovascular response triggered by whisker simulation in conditions of NOS blockade by superfusion of the brain surface with [l]{.smallcaps}-NNA ([@bib0270]). This suggested that NO might be essential for other signalling pathway(s) to operate by having something what one may call a "permissive" role. One report investigated the effect of systemic NOS blockade with [l]{.smallcaps}-NMMA on the neurovascular response in 10 human subjects ([@bib0465]). In contrast to the results obtained in the vast majority of animal studies, NOS blockade had no effect on neurovascular response when the participants performed a finger-tap task.

Several studies targeted another notable hypothesised pathway of neurovascular coupling which involves the release and vasodilator effects (on smooth muscle cells and capillary pericytes) of certain products of arachidonic acid metabolism including prostaglandins (PGs) and epoxyeicosatrienoic acids (EETs). All the enzymes required for the Ca^2+^-dependent production of arachidonic acid and PGs from membrane phospholipids are expressed in astrocytes ([@bib0315]), cells which are often placed at the centre of the neurovascular unit ([Fig. 1](#fig0005){ref-type="fig"}). PGs (PGE~2~ and PGI~2~ in particular) are potent vasodilators. Recent evidence has implicated PGE~2~ as the dominant prostaglandin mediating neurovascular coupling in the rodent cerebral cortex ([@bib0245]). However, there is also evidence obtained *in vitro* that PGE~2~ may, under certain conditions, constrict (rather than dilate) brain arterioles of rats and mice ([@bib0105]). Systematic review ([Fig. 2](#fig0010){ref-type="fig"}) has revealed that interfering with this pathway by either genetic deletion or pharmacological blockade of epoxygenase, inhibition of cyclooxygenases (COX) with non-specific agents or blockade of COX-2 specifically, results in a 55, 44 or 47% reduction in the magnitude of the neurovascular response, respectively. In humans, systemic non-specific COX inhibition was also reported to reduce the magnitude of the BOLD response induced by visual stimulation by 47% ([@bib0065]). It is important to note that indomethacin, used in all these studies as a non-specific COX inhibitor, is also a potent inhibitor of cyclic AMP-dependant protein kinase activity ([@bib0160]), which is integral to any vasomotor response. Therefore, conclusions drawn from the results of the experiments using indomethacin as a COX inhibitor may somewhat overestimate the importance of this pathway. For example, in humans indomethacin was found to reduce cerebrovascular CO~2~ reactivity, while the other non-specific COX inhibitors (naproxen, ketorolac) had no effect on CO~2~-induced dilations ([@bib0175]). On the other hand, the effects of specific inhibition or genetic elimination of COX-2 on neurovascular response were found to be similar to that of indomethacin, suggesting that off-target activity of this drug may not be relevant in this context. Specific pharmacological or genetic blockade of COX-1 activity was reported to reduce the neurovascular response by 24% on aggregate ([Fig. 2](#fig0010){ref-type="fig"}). Based on this analysis it would be logical to suggest that the actions of PGs and EETs mediate the proportion of the neurovascular response which remains after nNOS blockade. However, combined blockade of NOS and COX or NOS, COX and epoxygenase activity reduces the magnitude of the neurovascular response on average by 68% ([@bib0145]; [@bib0260]; [@bib0425]). This falls within the range of the effects observed following inhibition of nNOS activity alone ([Fig. 2](#fig0010){ref-type="fig"}).

NO, PGE~2~ and EETs dilate cerebral blood vessels by their actions on the arterial smooth muscle cells and/or capillary pericytes, and, therefore, act as the "effector" molecules of the neurovascular response. Studies of the mechanisms underlying the *initiation* of the response focused on the signalling molecules released by active neurones. Previously favoured models of the neurovascular coupling mechanism were centred on synaptic glutamate triggering Ca^2+^-dependent release of vasoactive substances by astrocytes ([@bib0030]). However, this model has been challenged by the evidence showing that mature astrocytes may not express appropriate glutamate receptors ([@bib0415]; but also see [@bib0340]) and that neuronal activity-induced changes in flow are not affected in the absence of astroglial IP~3~ receptors ([@bib0215]; [@bib0340]; [@bib0420]). We proposed in 2015 that (instead of glutamate) the release of purine nucleotide ATP may mediate signalling between neurones and astrocytes ([@bib0460]), a conclusion supported by the results of another study involving our laboratory ([@bib0315]). Astroglial IP~3~ receptors would not be essential for the operation of this mechanism as ATP may trigger Ca^2+^ responses in astrocytes *via* activation of ionotropic (P2X) receptors ([@bib0315]). Blockade of ATP actions (by facilitated enzymatic degradation) or application of purinoceptor antagonists was found to reduce the magnitude of the neurovascular response by 57% on average ([Fig. 2](#fig0010){ref-type="fig"}). Neurovascular response was also reported to be affected following blockade of other key neurotransmitter signalling pathways, including AMPA and NMDA receptors (inhibition by 44%), metabotropic glutamate receptor 5 (inhibition by 37%), muscarinic acetylcholine receptors (inhibition by 54%) or destruction of GABAergic neurones/pharmacological blockade of GABA receptors (inhibition by 24%) ([Fig. 2](#fig0010){ref-type="fig"}).

Released ATP is rapidly broken down to adenosine by the activities of extracellular nucleotidases ([Fig. 1](#fig0005){ref-type="fig"}). Seven studies targeted adenosine receptors (some are expressed by vascular smooth muscle cells) and reported (on average) a 53% reduction in the magnitude of the neurovascular response ([Fig. 2](#fig0010){ref-type="fig"}). One study involving combined nNOS and adenosine receptor blockade showed that 42% of the neurovascular response remains in these conditions ([@bib0115]), which is in the range of the effects elicited by NOS blockade alone ([Fig. 2](#fig0010){ref-type="fig"}), indicating no additive effect of adenosine receptor inhibition. In contrast, human studies demonstrated that non-selective adenosine receptor antagonist caffeine increases the magnitude of BOLD response to visual stimulation by as much as 37%, an effect which was suggested to be due to a reduction in the baseline flow ([@bib0320]). It is important to note that neurones express both the inhibitory (A~1~) and excitatory (*e.g.* A~2A,2B,3~) adenosine receptors, all sensitive to blockade by caffeine, which is also a weak inhibitor of phosphodiesterase activity, important for the maintenance of vascular tone and reactivity ([@bib0360]).

Another potential player which has been proposed to mediate the neurovascular response is potassium. Original data suggested that Ca^2+^-activated K^+^ (BK) channels on astroglial end-feet release K^+^ which in turn activates inward-rectifying K^+^ channels (K~IR~) expressed by smooth muscle cells, causing hyperpolarisation and relaxation ([@bib0130]). However, deletion of BK channels was found to have no effect on the neurovascular response ([@bib0140]). A modified hypothesis suggested that enhanced neuronal activity increases extracellular K^+^ sufficiently to trigger smooth muscle relaxation ([@bib0280]). Knock-out of a specific subunit, K~IR~2.1, was found to reduce the neurovascular response by ∼50% ([@bib0280]), while deletion of K~IR~6.1 had no effect ([@bib0180]). On aggregate, attempts to interfere with K^+^-mediated mechanism(s) resulted in 40% inhibition of the neurovascular response ([Fig. 2](#fig0010){ref-type="fig"}). The effects of these manipulations in combination with nNOS blockade remain to be determined.

While the data obtained using the *in vivo* preparations are in general agreement between the studies ([Fig. 2](#fig0010){ref-type="fig"}), the results obtained *in vitro* are largely inconsistent and represented by the extremes ([Fig. 3](#fig0015){ref-type="fig"}). For example, after NOS or COX inhibition the neurovascular response is either unaffected or completely inhibited ([Fig. 3](#fig0015){ref-type="fig"}). Accepted major caveats of the *in vitro* approach is that the integrity of the neurovascular unit is compromised and the vessels are not studied at optimal physiological tension, - the limitation which can be partially addressed by application of constricting agents ([@bib0125]). Studies of the vascular responses using the *in vitro* preparations also necessitate electrical stimulation to be applied in a close proximity to the site from which the neurovascular response is being recorded and could result in a pattern of neuronal connections and/or network recruitment that may not accurately reflect the activities of physiological neuronal pathways. This highlights the importance of studying the mechanisms of neurovascular coupling both *in vitro* and in conditions of intact synaptic connectivity, normal myogenic tone and blood flow. In the opinion of the authors of this analysis, *in vivo* animal models remain to be most useful for studies of the neurovascular coupling mechanisms as experiments involving human participants are also constrained by limitations imposed by the use of generally safe pharmacological agents and non-invasive methods of assessing changes in brain blood flow.

4. Regional segmentation {#sec0020}
========================

There is emerging evidence of functional regional segmentation of the cerebrovascular tree. Using vascular single-cell transcriptomics [@bib0450] demonstrated a clear gradual phenotypic change (zonation) along the continuum of the arteriovenous network in the mouse brain. Recent work has also suggested that the signalling mechanisms responsible for arteriolar *vs* capillary dilations are distinct and involve the release and actions of NO and PGE~2~, respectively ([@bib0315]). However, the majority of studies included in this analysis targeted specific hypothesised signalling mechanisms of neurovascular coupling without taking into the consideration the potential functional regional segmentation of the cerebral vessels capable of active dilation. In the opinion of the authors, the mechanism which controls the vascular tone at the point of most resistance to flow will play the key role in shaping the neurovascular response. According to the recent data reported by Charpak's group ([@bib0390]) this point (which the authors called "primary functional unit") could be around the first branching of the penetrating arteriole, as it dilates first in response to increases in local neuronal activity (in the mouse olfactory bulb).

We also do not discount the possibility that the mechanisms of the neurovascular response could vary by the brain region. This analysis included studies of neurovascular coupling in several brain regions, including olfactory bulb, cerebellum, visual, barrel and somatosensory cortical regions with the majority of the experiments carried out in the latter two. Only two studies included in the analysis reported complete abolition of the neurovascular response *in vivo*. In anesthetised rats, the neurovascular responses were blocked in the somatosensory forepaw region of the cortex after nNOS inhibition ([@bib0410]) and in the visual cortex, also in conditions of non-specific NOS inhibition ([@bib0205]). There is no *in vivo* evidence that the neurovascular response has been effectively blocked in any other brain region. In the absence of a clear consensus on key cell types and vascular segments mediating the neurovascular response in different brain regions, results of all the relevant studies were considered together, pooled and analysed by the targeted signalling pathway.

5. Conclusions {#sec0025}
==============

This analysis points to the existence of as yet an unidentified mechanism (or mechanisms) of neurovascular coupling which accounts for approximately a third of the neurovascular response. There are other precedents in the history of physiology illustrating the fact that the signalling mechanisms underlying activity-dependent changes in blood flow are sometimes difficult to identify. For example, the nature of the mediator(s) responsible for exercise-induced coronary vasodilation and increases in coronary blood flow (critically important to support myocardial oxygen demands) remains unclear despite similar research interest and significant effort. The involvement of common pathways was experimentally tested, but prostaglandins and K^+^ were found to play no role, while studies involving simultaneous blockade of K~ATP~ channels, NOS, and adenosine receptors demonstrated no effect of the combined treatment on exercise-induced changes in coronary blood flow ([@bib0150]). On the other hand, if functional hyperaemia is mediated by a single signalling molecule, then the underlying mechanism(s) can be rapidly and unequivocally identified ([@bib0075]).

Considering the importance of maintaining brain energy balance it is likely that there are several parallel signalling pathways evolved to work in concert to shape the neurovascular response and in conditions when one pathway is blocked experimentally, recruitment of the other pathway(s) compensates. However, this raises an obvious question of how the alternative pathways are engaged to maintain (at least partially) the vascular response when the targeted pathway is no longer functional. Some form of a feedback mechanism which can recruit these redundant pathway(s) when the need arises would be required. Alternatively, if the effects of parallel pathways are not simply additive, then a feedback mechanism may not be needed. It is not inconceivable that some form of negative synergy limits the effects of one signalling pathway when it operates in conjunction with the others in the intact system. Finally, in the opinion of the authors, full understanding of the complex mechanisms underlying the development and maintenance of the neurovascular response may emerge if some of the original ideas of metabolic feedback hypothesis proposed by [@bib0385] are re-examined using contemporary experimental approaches.
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